Latham & Watkins Advises Merus on Public Offering of Common Shares

Merus N.V. (Merus), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), has announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of US$24.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately US$120 million. In addition, Merus granted the underwriters a 30-day option to purchase up to an additional 727,272 common shares at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering are to be sold by Merus.

Latham & Watkins represented Merus N.V. in the transaction with a capital markets deal team led by partners Peter Handrinos and Wesley Holmes, with associates Jennifer Yoon, Emily Henderson, and Nuri Ruzi.